<DOC>
	<DOCNO>NCT01628107</DOCNO>
	<brief_summary>The purpose study determine long-term safety treatment-emergent adverse event ( TEAEs ) intravenous ( IV ) administration Epoetin Hospira maintenance target hemoglobin ( Hgb ) level patient treat anemia associate chronic renal failure hemodialysis .</brief_summary>
	<brief_title>A Phase 3 , Long-Term Safety Study Intravenous Epoetin Hospira Patients With Chronic Renal Failure Requiring Hemodialysis Receiving Epoetin Maintenance Treatment . AiME - Anemia Management With Epoetin</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Patient able provide write Informed Consent risk benefit study explain prior studyrelated activity . 2 . Patient previously complete core study Treatment Period include Week 24 study assessment per protocol willing continue openlabel Epoetin Hospira 48 week . 3 . If female , patient must postmenopausal least 1 year prior enrollment , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , practice least 1 follow method birth control : Hormonal contraceptive ( oral , parenteral , transdermal ) least 3 month prior enrollment Intrauterine device Doublebarrier method ( condom , contraceptive sponge , diaphragm , vaginal ring spermicidal jelly cream ) If hormonal contraceptive use , specific contraceptive must use least 3 month prior enrollment . If patient currently use hormonal contraceptive , also use barrier method study least 30 day follow administration patient 's last openlabel dose . 4 . Adequate method contraception prevent pregnancy maintain throughout course study male female study subject . 1 . Patient serious severe adverse event core study , opinion Investigator , probably definitely related epoetin use preclude safe use epoetin . 2 . Any following developed core study prior enrollment : Myocardial infarction Stroke ( cerebrovascular accident ) /cerebrovascular insult ( minor stroke ) transient ischemic attack/intracerebral bleeding/cerebral infarction Severe/unstable angina Coronary angioplasty , bypass surgery , peripheral artery bypass graft Decompensated congestive heart failure ( New York Heart Association [ NYHA ] class IV ) Pulmonary embolism Deep vein thrombosis thromboembolic event Received live attenuate vaccination ( except flu vaccination ) 3 . A patient active , uncontrolled systemic , inflammatory , malignant disease develop core study Investigator 's opinion may significant exclude participation study , include limited demyelinating disease multiple sclerosis , microbial , viral , fungal infection mental disease . 4 . Any newly develop significant drug sensitivity significant allergic reaction drug , well know hypersensitivity idiosyncratic reaction epoetin ( excipients , include albumin ) relate drug judgment Investigator exclusionary study participation . 5 . A female patient pregnant , lactate , plan pregnancy study . 6 . History drug abuse alcohol abuse core study prior enrollment determine Investigator . 7 . Current participation participation drug investigational research study within 30 day prior enrollment ( except core study observational study prior write approval Hospira ) . 8 . May able comply requirement clinical study , communicate effectively study personnel , consider Investigator , reason , unsuitable candidate study . 9 . Evidence human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) . 10 . A patient , Investigator 's opinion , clinically significant abnormal laboratory result may impact patient safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Chronic renal failure</keyword>
	<keyword>hemodialysis</keyword>
</DOC>